Tumor-promoting inflammation is a new concept of immune modality intervention, as it was demonstrated that inflammation has a fundamental role in tumorigenesis and progression in KRAS-mutant NSCLC. This evidence concerns the gene KRAS and non-small cell lung carcinoma.